Longboard Pharmaceuticals, Inc. (LBPH)

Market Cap	89.30M
Revenue (ttm)	n/a
Net Income (ttm)	-43.95M
Shares Out	22.97M
EPS (ttm)	-2.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108
Open	4.09
Previous Close	4.05
Day's Range	4.09 - 4.09
52-Week Range	2.70 - 6.23
Beta	1.16
Analysts	Buy
Price Target	17.85 (+336.43%)
Earnings Date	May 3, 2023

About LBPH

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Lo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 12, 2021
• Employees: 21
• Stock Exchange: NASDAQ
• Ticker Symbol: LBPH

Analyst Forecast

According to 12 analysts, the average rating for LBPH stock is "Buy." The 12-month stock price forecast is $17.85, which is an increase of 336.43% from the latest price.

Price Target

$17.85

(336.43% upside)

Analyst Consensus: Buy